Market News & Trends
Maze Therapeutics Doses First Patient in Phase 2 Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease
Maze Therapeutics, Inc. recently announced the first patient has been dosed in the company’s Phase 2 clinical trial, the HORIZON Study, of MZE829 in patients…
Thermo Fisher Scientific Launches International CorEvitas Clinical Registry in Adolescent Alopecia Areata
Thermo Fisher Scientific Inc. recently announced the launch of the international CorEvitas Adolescent Alopecia Areata (AA) Registry, addressing a critical unmet need for real-world, adolescent-specific…
Gradalis Secures FDA Regenerative Medicine Advanced Therapy Designation for Investigational Personalized Immunotherapy for Advanced Ovarian Cancer
Gradalis, Inc. recently announced the US FDA has granted Gradalis’ personalized investigational cellular immunotherapy, Vigil (Gemogenovatucel-T) Regenerative Medicine Advanced Therapy (RMAT) designation based on favorable clinical…
Indaptus Therapeutics Receives Approval From Health Canada to Expand Clinical Trial of Decoy20
Indaptus Therapeutics, Inc. recently announced it has received Clinical Trial Authorization from Health Canada to initiate its clinical trial for its lead asset, Decoy20. This…
Annovis Announces First Patients Entered Into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer’s Disease
Annovis Bio Inc. recently announced the first two patients have been entered into the pivotal Phase 3 study evaluating buntanetap in early AD. "The launch…
Quantum Biopharma Announces the Success of unbuzzd Clinical Trial
Quantum BioPharma Ltd. recently announced it has completed a double-blind, randomized, placebo-controlled crossover design clinical trial (NCT06505239) of its dietary supplement product unbuzzd, investigating its…
Gelteq Launches SportsGel Brand & Signs Distribution Agreement With E-Commerce Solutions Company
Gelteq Limited recently announced the launch of its SportsGel brand. “SportsGel has been established to eliminate the common trade-off between performance versus taste, mouthfeel and…
Ardena Completes Acquisition of Advanced Drug Product Manufacturing Facility From Catalent & Expands Bioanalytical Services in North America
Ardena recently announced it has successfully completed the acquisition of Catalent’s state-of-the-art drug product manufacturing facility in Somerset, NJ. This acquisition marks a significant milestone…
Northstrive Biosciences Reports Positive Updates for Obesity Drug Candidates
Northstrive Biosciences Inc. recently announced an update for its innovative obesity treatment candidates, EL-22 and EL-32, both aimed at optimizing fat loss while preserving muscle…
BioNTech Completes Acquisition of Biotheus
BioNTech SE recently announced the completion of the acquisition of Biotheus, a clinical-stage biotechnology company dedicated to the discovery and development of novel antibodies to…
Purple Biotech Announces Research Collaboration With the Icahn School of Medicine at Mount Sinai
Purple Biotech Ltd. recently announced it has entered into a Research Collaboration Agreement with the Icahn School of Medicine at Mount Sinai (Icahn School of…
HCW Biologics Granted FDA Clearance to Evaluate One of its Lead Product Candidates in a First-In-Human Phase 1 Clinical Trial
HCW Biologics Inc. recently announced it has received clearance of its Investigational New Drug Application (IND) from the US FDA to initiate a first-in-human Phase…
Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-Initiated Phase 1/2 Clinical Trial Using Seclidemstat With Azacitidine to Treat Hematologic Cancers
Salarius Pharmaceuticals, Inc. recently announced patient enrollment will resume in the investigator-initiated Phase 1/2 clinical trial evaluating seclidemstat in combination with azacitidine for the treatment…
Jupiter Neurosciences Announces Manufacturing Agreement With Catalent
Jupiter Neurosciences, Inc. recently announced it has entered into an agreement with Catalent Pharma Solutions, LLC for the production of JOTROL softgel capsules to support…
Nuvation Bio Announces Expanded Access Program in the US for Taletrectinib in Advanced ROS1-Positive Non-Small Cell Lung Cancer
Nuvation Bio Inc. recently announced it has initiated an Expanded Access Program (EAP) for taletrectinib in the US for the treatment of patients with locally…
SGS Introduces First Commercial Cell Sorting Service for the Biopharmaceutical Industry
SGS, the world’s leading testing, inspection and certification company, is proud to announce the launch of Germany’s first commercial cell sorting service via fluorescent-activated cell…
Jupiter Neurosciences Partners With Zina Biopharmaceuticals to Advance Phase 2a Parkinson’s Trial
Jupiter Neurosciences, Inc. recently announced a strategic partnership with Zina Biopharmaceuticals, LLC to support all aspects of Jupiter’s upcoming Phase 2a clinical trial for Parkinson’s…
Rentschler Biopharma Announces Strategic Realignment of its Global Business Operations
Rentschler Biopharma SE recently announced a realignment of its global business operations as part of a long-term strategic shift. As part of this realignment, Rentschler…
Northstrive Biosciences Signs Agreement for a Potential Breakthrough Obesity Therapy Targeting Fat Loss & Muscle Preservation in Combination With GLP-1
PMGC Holdings Inc. (formerly Elevai Labs Inc.) recently announced that its subsidiary, Northstrive Biosciences Inc., has executed a research agreement with a leading preclinical contract…
Ocean Biomedical Advances Malaria Vaccine Research With New NIH Funding & Expedited Development Pathway
Ocean Biomedical recently announced its Scientific Co-founder, Dr. Jonathan Kurtis, MD, PhD, and his research team have received additional significant funding from the National Institutes…
